← back to search

Thomas R. Arkell

Swinburne University of Technology · AU
Area of research
Pharmacology · Toxicology
Research interest
Research interests include Cannabis and Cannabinoid Research, Forensic Toxicology and Drug Analysis, Substance Abuse Treatment and Outcomes, and Psychedelics and Drug Studies.
h-index
15
citations
1,196
works
46
NIH funding
primary concept
email

Recent publications

Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022–2023 (CAMS-22)
Harm Reduction Journal 2024cited by 18position: middledoi
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis
Psychopharmacology 2022cited by 36position: middledoi
Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review
Neuroscience & Biobehavioral Reviews 2021cited by 164position: middledoi
The failings of <i>per se</i> limits to detect cannabis-induced driving impairment: Results from a simulated driving study
Traffic Injury Prevention 2021cited by 56position: firstdoi
Are blood and oral fluid Δ9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis
Neuroscience & Biobehavioral Reviews 2021cited by 51position: middledoi
Effect of Cannabidiol and Δ<sup>9</sup>-Tetrahydrocannabinol on Driving Performance
JAMA 2020cited by 170position: firstdoi
Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)
Harm Reduction Journal 2020cited by 144position: middledoi
Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey
Accident Analysis & Prevention 2020cited by 50position: firstdoi
Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
Psychopharmacology 2019cited by 175position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Nicholas Lintzeris · St. Leonards Hospital4 papers (2019–2024)Anastasia Suraev · The University of Sydney3 papers (2020–2024)Christopher Irwin · University of Queensland3 papers (2019–2021)Jonathon C. Arnold · The University of Sydney3 papers (2020–2024)Llewellyn Mills · The University of Sydney3 papers (2020–2024) · 3 papers (2019–2022)Danielle McCartney · The University of Sydney2 papers (2021–2021) · 2 papers (2020–2022)Ryan G. Vandrey · Johns Hopkins University2 papers (2019–2021) · 2 papers (2020–2022)Melissa J. Benson · University of Sydney1 papers (2020–2020)Sarah V. Abelev · The University of Notre Dame Australia1 papers (2024–2024)Tory R. Spindle · Virginia Commonwealth University1 papers (2021–2021) · 1 papers (2022–2022)Paul Haber · Alcohol and Drug Foundation1 papers (2019–2019)Jan Schepers · KU Leuven1 papers (2022–2022)Cilla Zhou · National Centre for Clinical Research on Emerging Drugs1 papers (2024–2024) · 1 papers (2022–2022)